+39 02 610346.1 - info@newron.com

Success in CNS drug development – Innovation in Rare Diseases

We are a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. Our shares are listed on the SIX Swiss Exchange (NWRN).

Latest press releases

  • 5Mar
    Newron announces 2018 financial results and provides outlook for 2019

     

  • 28Feb
    Newron Supports Global Rare Disease Day® 2019

     

  • 20Feb
    Newron to Present at the 8th Annual SVB Leerink Global Healthcare Conference

  • 1Feb
    Newron Completes Patient Enrollment in Pivotal STARS Study

     

  • 31Jan
    Newron Pharmaceuticals to Present at the 21st Annual BIO CEO & Investor Conference in New York

  • 16Jan
    Zambon together with Valeo Pharma announce the approval of Onstryv® (safinamide) for PD in Canada

View All

Newron share price

Events

  • 7May
    Swiss Biotech Day 2019

    May 7, 2019 - Congress Center, Basel, Switzerland

  • 16Apr
    12th Kempen Life Sciences Conference

    April 16-17, 2019 - Amsterdam, The Netherlands

  • 7Apr
    H.C. Wainwright Global Life Sciences Conference 2019

    April 7-9, 2019 - Grosvenor House, London, UK

View Event Calendar